Background and Aims We conducted a systematic review and meta-analysis to summarize
emerging data on the safety and effectiveness of dual biologic therapy in combination or …

Increased knowledge of the intricate pathogenesis of ulcerative colitis has triggered an
advance in drug development during the past two decades, resulting in the advent of several …

Background Despite the introduction of new monoclonal antibodies and oral therapies for
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Background Biologic therapies in patients with Crohn's disease often yield low clinical and
endoscopic remission rates. After multiple failed therapies, combining two biologic therapies …

Background Combining biologics and small molecules could potentially overcome the
plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic …

The expanding therapeutic armamentarium available for inflammatory bowel disease (IBD)
as well as multiple compounds in clinical development inevitably raises questions as to their …

Background Combining immunosuppressors has been proposed as a strategy to enhance
treatment efficacy in Inflammatory Bowel Disease (IBD). Aim To summarize current evidence …

Methods This was a medical record–based, retrospective study of established CD or UC
patients who were treated with infliximab, adalimumab, certolizumab pegol, golimumab …

Inflammatory bowel disease (IBD) management has changed dramatically over the past 20
years, after the introduction of targeted biological therapies. However, the impact of these …